Literature DB >> 23756055

Acyclovir-resistant varicella-zoster virus keratitis in an immunocompetent patient.

J Gueudry1, D Boutolleau, M Gueudin, S Burrel, A Miri, B Bodaghi, M Muraine.   

Abstract

Varicella-zoster virus (VZV) resistance to acyclovir (ACV) has only been reported in rare cases of immunocompromised patients. We report the first case of an immunocompetent patient with ACV-resistant VZV keratitis associated with a nucleotide deletion in the VZV thymidine kinase gene, leading to production of a truncated protein.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acyclovir; Cornea; Drug resistance; Herpetic keratitis; Varicella zoster virus

Mesh：

Substances：

Year:  2013        PMID： 23756055     DOI： 10.1016/j.jcv.2013.04.024

Source DB:  PubMed          Journal:  J Clin Virol        ISSN： 1386-6532            Impact factor:   3.168


  4 in total

1.  Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies.

Authors:  Farah Sahoo; Joshua A Hill; Hu Xie; Wendy Leisenring; Jessica Yi; Sonia Goyal; Louise E Kimball; Ingi Lee; Sachiko Seo; Chris Davis; Stephen A Pergam; Mary E Flowers; Kai-Li Liaw; Leona Holmberg; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-28       Impact factor: 5.742

2.  Herpes zoster keratitis development after acute retinal necrosis.

Authors:  Waseem H Ansari; Francesco Pichi; Paula E Pecen; Careen Y Lowder; Sunil K Srivistava
Journal:  Int Ophthalmol       Date:  2017-04-22       Impact factor: 2.031

Review 3.  Pathobiology and treatment of viral keratitis.

Authors:  Raghuram Koganti; Tejabhiram Yadavalli; Raza Ali Naqvi; Deepak Shukla; Afsar R Naqvi
Journal:  Exp Eye Res       Date:  2021-02-06       Impact factor: 3.467

Review 4.  Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.